Crown Laboratories, Inc. (“Crown”), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings.
Jeff Bedard, Founder and Chief Executive Officer of Crown commented, “We are excited to officially welcome Revance to the Crown family. This acquisition strengthens our leadership position and enhances our ability to deliver innovative solutions to customers, with what we believe is a comprehensive portfolio that represents the three pillars of facial aesthetics – relax, restore, and regenerate – and we will support these offerings with a highly trained and experienced sales force. We are well-positioned to become a global leader in the aesthetics and skincare industry and will leverage our combined resources to create long-term value for our stakeholders.”